Wells Fargo’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.5K | Sell |
3,980
-7,782
| -66% | -$55.4K | ﹤0.01% | 5699 |
|
|
2025
Q4 | $84.8K | Buy |
11,762
+3,878
| +49% | +$31.4K | ﹤0.01% | 5441 |
|
|
2025
Q3 | $80.6K | Buy |
7,884
+2,051
| +35% | +$23.1K | ﹤0.01% | 5412 |
|
|
2025
Q2 | $60.6K | Buy |
5,833
+878
| +18% | +$9.35K | ﹤0.01% | 5447 |
|
|
2025
Q1 | $65.3K | Buy |
4,955
+108
| +2% | +$1.93K | ﹤0.01% | 5302 |
|
|
2024
Q4 | $86.8K | Buy |
4,847
+2,568
| +113% | +$52K | ﹤0.01% | 5275 |
|
|
2024
Q3 | $36.7K | Sell |
2,279
-88
| -4% | -$1.38K | ﹤0.01% | 5458 |
|
|
2024
Q2 | $63.9K | Buy |
2,367
+1,025
| +76% | +$24.5K | ﹤0.01% | 5191 |
|
|
2024
Q1 | $26.2K | Buy |
1,342
+169
| +14% | +$3.58K | ﹤0.01% | 5494 |
|
|
2023
Q4 | $24.3K | Buy |
1,173
+246
| +27% | +$7.34K | ﹤0.01% | 5562 |
|
|
2023
Q3 | $29.5K | Sell |
927
-603
| -39% | -$20.1K | ﹤0.01% | 5438 |
|
|
2023
Q2 | $51.4K | Buy |
1,530
+1,484
| +3,226% | +$53.1K | ﹤0.01% | 5417 |
|
|
2023
Q1 | $1.9K | Buy |
46
+20
| +77% | +$940 | ﹤0.01% | 6232 |
|
|
2022
Q4 | $884 | Buy |
26
+1
| +4% | +$43 | ﹤0.01% | 6225 |
|
|
2022
Q3 | $1K | Sell |
25
-3
| -11% | -$165 | ﹤0.01% | 6444 |
|
|
2022
Q2 | $1K | Sell |
28
-3,035
| -99% | -$90K | ﹤0.01% | 6586 |
|
|
2022
Q1 | $113K | Sell |
3,063
-834
| -21% | -$52.2K | ﹤0.01% | 5264 |
|
|
2021
Q4 | $381K | Sell |
3,897
-763
| -16% | -$82.1K | ﹤0.01% | 4881 |
|
|
2021
Q3 | $581K | Buy |
4,660
+2,832
| +155% | +$342K | ﹤0.01% | 4583 |
|
|
2021
Q2 | $229K | Buy |
1,828
+1,061
| +138% | +$126K | ﹤0.01% | 4970 |
|
|
2021
Q1 | $105K | Sell |
767
-3,085
| -80% | -$383K | ﹤0.01% | 5461 |
|
|
2020
Q4 | $350K | Sell |
3,852
-1,454
| -27% | -$126K | ﹤0.01% | 4783 |
|
|
2020
Q3 | $394K | Buy |
5,306
+1,111
| +26% | +$85.1K | ﹤0.01% | 4523 |
|
|
2020
Q2 | $357K | Buy |
4,195
+4,189
| +69,817% | +$380K | ﹤0.01% | 4555 |
|
|
2020
Q1 | $0 | Buy |
+6
| New | +$579 | ﹤0.01% | 6693 |
|
|
2019
Q3 | – | Sell |
-64
| Closed | -$4K | – | 6649 |
|
|
2019
Q2 | $4K | Sell |
64
-229
| -78% | -$15.6K | ﹤0.01% | 6078 |
|
|
2019
Q1 | $21K | Sell |
293
-1
| -0.3% | -$63 | ﹤0.01% | 5524 |
|
|
2018
Q4 | $23K | Sell |
294
-503
| -63% | -$115K | ﹤0.01% | 5747 |
|
|
2018
Q3 | $372K | Buy |
797
+3
| +0.4% | +$1.21K | ﹤0.01% | 4640 |
|
|
2018
Q2 | $316K | Buy |
794
+46
| +6% | +$16.3K | ﹤0.01% | 4768 |
|
|
2018
Q1 | $229K | Sell |
748
-35
| -4% | -$9.97K | ﹤0.01% | 4909 |
|
|
2017
Q4 | $230K | Buy |
783
+436
| +126% | +$191K | ﹤0.01% | 4891 |
|
|
2017
Q3 | $190K | Buy |
347
+174
| +101% | +$92.5K | ﹤0.01% | 4959 |
|
|
2017
Q2 | $103K | Hold |
173
| – | – | ﹤0.01% | 5162 |
|
|
2017
Q1 | $74K | Hold |
173
| – | – | ﹤0.01% | 5316 |
|
|
2016
Q4 | $89K | Buy |
+173
| New | +$101K | ﹤0.01% | 5208 |
|
Other funds holding RNAC
VCM
6CM
EAM
Wells Fargo's RNAC Position: Q1 2026 in Review
Wells Fargo reduced its Cartesian Therapeutics (RNAC) stake by 66% in Q1 2026, selling an estimated $55.4K and leaving 3,980 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5699.
Wells Fargo first reported a position in RNAC in Q4 2016 and has held it in 36 quarters since. The position peaked at $581K in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Wells Fargo held 3,980 shares of Cartesian Therapeutics worth $24.5K as of Q1 2026.
- Wells Fargo sold 7,782 Cartesian Therapeutics shares in Q1 2026, an estimated $55.4K.
- Cartesian Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5699 holding.
- Wells Fargo first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 36 quarters since.
- Wells Fargo's Cartesian Therapeutics position peaked at $581K in Q3 2021.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.